United Kingdom Archives

More News! 30 May 2017

FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford

The FDA has handed out a Fast Track Designation to AMO Pharma for its key asset AMO-02 to treat congenital myotonic dystrophy. The British-American biotech hybrid AMO Pharma is advancing a small pipeline of drugs for rare genetic disorders. The biotech, which is backed by famous UK Investor Neil Woodford, is currently pushing its lead candidate […]

May 30, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 26 May 2017

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the drug for its NDA submission to the FDA and led some to forecast blockbuster success. Original Publication 30/03/2016 GW Pharmaceuticals (UK) has announced positive results […]

May 26, 2017 - 4 minutesmins - By Ekaterina Perets

News and Trends 24 May 2017

UK biotech is catching up to the US, but will it run out of gas?

The UK is far ahead of its European biotech rivals according to a new report, but will it fulfill its promise of becoming a global hub? According to analysis by the BioIndustry Association, the UK is catching up to global biotech leaders San Francisco and Boston, both in finance and R&D. British biotechs banked £1.13B last year, and […]

May 24, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 18 May 2017

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches. Heptares, owned by Sosei and based just outside London, will take home €4.5M ($5M) from Teva for discovering a drug candidate for migraine treatment. The small molecule is an calcitonin gene-related peptide (CGRP) agonist that could relieve patients […]

May 18, 2017 - 1 minutemin - By Evelyn Warner

Interview 15 May 2017

Meet the CEO developing the Next Generation of Antibody Therapeutics

Crescendo Biologics has positioned itself as the successor of Cambridge Antibody Technology and a new rival to Morphosys. We interviewed CEO Peter Pack. Peter Pack started working in life science 25 years ago — “quite a long time ago,” he laughs. “I’m an old guy now.” Now the CEO of Crescendo Biologics, whose Humabody platform […]

May 15, 2017 - 8 minutesmins - By Evelyn Warner

Rebecca Harris Symbiosis Invisible You Microbiome

News and Trends 13 May 2017

Visualizing the Microbiome through Handmade Embroidery

Rebecca Harris is a British artist that uses handmade embroidery to visually communicate the huge diversity of microbes that form part of our bodies. Trillions of microbes live on us and inside us. “Microbes are essential for our well-being and development. The microbes stimulate and develop the immune response, and they detoxify harmful carcinogenic compounds in our […]

May 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 May 2017

HIV Treatment Development Extends Life Expectancy by 10 Years

According to a new study, the life expectancy of 20-year-olds starting HIV treatment has increased by a decade in the EU and North America. A massive new study from the UK was published today in The Lancet HIV. The study tracked how many HIV patients died during the first three years of HIV treatment, their cause […]

May 11, 2017 - 3 minutesmins - By Melanie De Almeida

Interview 10 May 2017

Video: Meet the CEO fighting Cancer with Mycobacteria

Clara talked to Linda Summerton, CEO of Immodulon Therapeutics, about the company’s project of applying the microbiome to immuno-oncology. As R&D efforts in the microbiome gain traction, Clara talked to the head of one of the most valuable companies in the UK, Immodulon Therapeutics. When asked about Forbes’ valuation of her company at £400M, Linda Summerton laughed, “That’s […]

May 10, 2017 - 3 minutesmins - By Evelyn Warner

Interview 9 May 2017

Video Interview: Meet the Oxford COO improving Tech Transfer

Adam Stoten is the new COO of Oxford University Innovation. Philip caught up with him at BioTrinity in London to talk about tech transfer. Both from academic and industrial perspectives, tech transfer has a reputation for being an onerous process. But some organizations are working steadfastly to streamline it with great success, like Oxford University Innovation. […]

May 9, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 9 May 2017

AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal

As part of the deal with Sanofi, Exscientia will tackle the discovery and design of new bispecific drugs using artificial intelligence algorithms. Exscientia, based in Scotland, is a company that uses artificial intelligence (AI) to develop new drugs faster. Its edge-cutting technology has caught the attention of Sanofi, which is offering Exscientia research funding and […]

May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

GammaDelta Therapeutics Takeda Collaboration 1

More News! 9 May 2017

British Biotech Startup Partners with Takeda to Advance its T Cell Platform

GammaDelta Therapeutics and Takeda have formed a strategic collaboration to develop a novel T cell platform, which is based on gamma delta (γδ) T cells. Based in London, GammaDelta Therapeutics builds on the work of Adrian Hayday and Oliver Nussbaumer of Kings College London and The Francis Crick Institute. Backed by the huge British VC […]

May 9, 2017 - 2 minutesmins - By Melanie De Almeida

More News! 9 May 2017

Scottish Shark Antibodies have caught Amgen’s Eye

Elasmogen and its partner Feldan Therapeutics have signed a research agreement with Amgen to develop shark-inspired antibodies delivered intracellularly. Elasmogen, based in Aberdeen, Scotland, develops soloMER‘s, which are the smallest naturally-occurring antibody binding domains. “They are remarkably stable,” Caroline Barelle told me this morning at BioTrinity in London. “They can survive extreme pH and temperatures […]

May 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Approaches

Therapeutic areas

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

United Kingdom

FDA Fast Tracks Muscular Dystrophy Drug backed by Woodford

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

UK biotech is catching up to the US, but will it run out of gas?

Heptares receives €4.5M Milestone for New Migraine Drug Candidate

Meet the CEO developing the Next Generation of Antibody Therapeutics

Visualizing the Microbiome through Handmade Embroidery

HIV Treatment Development Extends Life Expectancy by 10 Years

Video: Meet the CEO fighting Cancer with Mycobacteria

Video Interview: Meet the Oxford COO improving Tech Transfer

AI-Based Drug Discovery Biotech is Recruited by Sanofi in €250M Deal

British Biotech Startup Partners with Takeda to Advance its T Cell Platform

Scottish Shark Antibodies have caught Amgen’s Eye

Subscribe to our newsletter to get the latest biotech news!

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

10 oncology deals in 2025 spotlight where industry leaders are betting big

10 biotech companies leading the way in Denmark

Webinar: Advancements in antimalarial drug discovery and development

Six psychedelic drug companies aiming to revolutionize mental health treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!